Human antimicrobial peptide LL-37 is present in atherosclerotic plaques and induces death of vascular smooth muscle cells: A laboratory study

被引:58
作者
Ciornei C.D. [1 ]
Tapper H. [2 ]
Bjartell A. [3 ]
Sternby N.H. [4 ]
Bodelsson M. [1 ]
机构
[1] Department of Clinical Sciences, Division of Anaesthesiology and Intensive Care, Lund University, Lund
[2] Department of Clinical Sciences, Division of Clinical and Experimental Infection Medicine (BMC), Lund University, Lund
[3] Department of Clinical Sciences, Lund University, Malmö University Hospital, Malmö
[4] Department of Laboratory Medicine, Lund University, Malmö University Hospital, Malmö
关键词
Smooth Muscle Cell; Propidium Iodide; Vascular Smooth Muscle Cell; Atherosclerotic Plaque; Atherosclerotic Lesion;
D O I
10.1186/1471-2261-6-49
中图分类号
学科分类号
摘要
Background: Death of smooth muscle cells in the atherosclerotic plaques makes the plaques more prone to rupture, which can initiate an acute ischemic event. The development of atherosclerosis includes the migration of immune cells e.g. monocytes/macrophages and T lymphocytes into the lesions. Immune cells can release antimicrobial peptides. One of these, human cathelicidin antimicrobial peptide hCAP-18, is cleaved by proteinase 3 generating a 4.5 kDa C-terminal fragment named LL-37, which has been shown to be cytotoxic. The aim of the study was to explore a potential role of LL-37 in the pathophysiology of atherosclerosis. Methods: We investigated the presence of LL-37 in human atherosclerotic lesions obtained at autopsy using immunohistochemistry. The direct effects of LL-37 on cultured vascular smooth muscle cells and isolated neutrophil granulocytes were investigated with morphological, biochemical and flow cytometry analysis. Results: The neointima of athe rosclerotic plaques was found to contain LL-37-like immunoreactivity, mainly in macrophages. In cultured smooth muscle cells, LL-37 at 30 μg/ml caused cell shrinkage, membrane blebbing, nuclear condensation, DNA fragmentation and an increase in caspase-3 activity as studied by microscopy, ELISA and enzyme activity assay, respectively. Flow cytometry demonstrated that LL-37 in a subset of the cells caused a small but rapidly developing increase in membrane permeability to propidium iodide, followed by a gradual development of FITC-annexin V binding. Another cell population stained heavily with both propidium iodide and FITC-annexin V. Neutrophil granulocytes were resistant to these effects of LL-37. Conclusion: This study shows that LL-37 is present in atherosclerotic lesions and that it induces death of vascular smooth muscle cells. In a subset of cells, the changes indicate the development of apoptosis triggered by an initial mild perturbation of plasma membrane integrity. The findings suggest a role for LL-37 as a mediator of immune cell-induced death of vascular smooth muscle cells in atherosclerosis. © 2006 Ciornei et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 58 条
[1]
Rekhter M.D., Collagen synthesis in atherosclerosis: Too much and not enough, Cardiovasc Res, 41, pp. 376-384, (1999)
[2]
Geng Y.J., Libby P., Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme, Am J Pathol, 147, pp. 251-266, (1995)
[3]
Kockx M.M., De Meyer G.R., Muhring J., Jacob W., Bult H., Herman A.G., Apoptosis and related proteins in different stages of human atherosclerotic plaques, Circulation, 97, pp. 2307-2315, (1998)
[4]
Glass C.K., Witztum J.L., Atherosclerosis. The road ahead, Cell, 104, pp. 503-516, (2001)
[5]
Hansson G.K., Immune mechanisms in atherosclerosis, Arterioscler Thromb Vasc Biol, 21, pp. 1876-1890, (2001)
[6]
Hancock R.E., Chapple D.S., Peptide antibiotics, Antimicrob Agents Chemother, 43, pp. 1317-1323, (1999)
[7]
Gennaro R., Zanetti M., Structural features and biological activities of the cathelicidin-derived antimicrobial peptides, Biopolymers, 55, pp. 31-49, (2000)
[8]
Cowland J.B., Johnsen A.H., Borregaard N., hCAP-18, a cathelin/pro-bactenecin-like protein of human neutrophil specific granules, FEBS Lett, 368, pp. 173-176, (1995)
[9]
Larrick J.W., Hirata M., Zhong J., Wright S.C., Anti-microbial activity of human CAP18 peptides, Immunotechnology, 1, pp. 65-72, (1995)
[10]
Agerberth B., Gunne H., Odeberg J., Kogner P., Boman H.G., Gudmundsson G.H., FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis, Proc Natl Acad Sci U S A, 92, pp. 195-199, (1995)